Scientific Presentations

durvalumab-photoA Phase 1/2 study of durvalumab alone or in combination with AXAL in recurrent/persistent or metastatic cervical or human papillomavirus (HPV)+ squamous cell cancer of the head and neck (SCCHN): Preliminary Phase 1 results
Uploaded: November 11, 2016
Type: PDF
aim2cerv-photoAIM2CERV: a randomized phase 3 study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC)
Uploaded: November 11, 2016
Type: PDF
preclinical-photoCombination of Listeria-based human papillomavirus (HPV)-E7 cancer vaccine (AXAL) with CD137 agonistic antibody provides an effective immunotherapy for HPV+ tumors in a mouse model
Uploaded: November 11, 2016
Type: PDF
ASCO1ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study Poster
Uploaded: June 6, 2016
Type: PDF
Poster presentationADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study Presentation
Uploaded: June 6, 2016
Type: PDF
1-adxAACR research reception presentation; featuring late-breaking poster on Lm Technology™ platform
Uploaded: Apr 19, 2015
Type: PDF
1-adxHPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity – AACR 2016
Uploaded: Apr 18, 2015
Type: PDF
 1-adxPhase 1/2 study of ADXS31-142 and pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial – SITC 2015
Uploaded: Nov 5, 2015
Type: PDF
 adxs11Phase 1/2 study of ADXS11-001 or Durvalumab in recurrent/metastatic cervical or HPV-positive head and neck cancer – SITC 2015
Uploaded: Nov 5, 2015
Type: PDF
 adxs11-2High-dose treatment with ADXS11-001 in women with cervical cancer – SITC 2015
Uploaded: Nov 5, 2015
Type: PDF
 stage-1Stage 1 Clinical Data from Phase 2 GOG 0265 Study in Metastatic Cervical Cancer – AGOS 2015
Uploaded: Sep 17, 2015
Type: PDF
 5-immuntherapyImmunotherapy of Breast Cancer – World Congress on Breast Cancer
Uploaded: Aug 4, 2015
Type: PDF
 6-combinationCombination Lm-LLO Immunotherapy plus Radiation Delays Tumor Progression and Prolongs Survival in Osteosarcoma
Uploaded: Jun 8, 2015
Type: PDF
 7-case1studyPhase 1 study evaluating high-dose ADXS11-001 treatment in women with carcinoma of the cervix
Uploaded: Jun 1, 2015
Type: PDF
 8-widowWindow of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer
Uploaded: Jun 1, 2015
Type: PDF
 9-phase1Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix
Uploaded: May 26, 2015
Type: Link
 10-windowWindow of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer
Uploaded: May 26, 2015
Type: Link
 11-agnosticAgonistic antibodies to co-stimulatory molecules, OX40 and GITR, significantly enhance the anti-tumor efficacy of Listeria monocytogenes (Lm-LLO)-based immunotherapy
Uploaded: Apr 23, 2015
Type: Link
 12-anti-tumorAnti-Tumor Therapeutic Effects in Mice Treated with Listeria Monocytogenes (Lm)-LLO Immunotherapy in Combination with Anti-PD-L1
Uploaded: Apr 21, 2015
Type: PDF
 13-lm-lloLM-LLO-HER2/NEU Immunotherapy Combined with Radiation Safely Delays Tumor Progression and Prolongs Overall Survival in a Phase I Clinical Study in Canine Osteosarcoma
Uploaded: Apr 21, 2015
Type: PDF
 14-phaseA Phase 1/2 Evaluation of ADXS11- 001 Lm-LLO Immunotherapy, Mitomycin, 5-Fluoruracil (5-FU) and IMRT for Anal Cancer
Uploaded: Mar 16, 2015
Type: PDF
 15-advADXS11-001 Lm-LLO Cancer Immunotherapy: Final Results and Long-Term Survival Data From a Randomized Phase 2 Study in Recurrent Cervical Cancer
Uploaded: Nov 10, 2014
Type: PDF
 16-recombinantA recombinant HER2/Neu expressing Listeria monocytogenes (Lm-LLO) immunotherapy delays metastaAc disease and prolongs overall survival in a spontaneous canine model of osteosarcoma
Uploaded: Nov 10, 2014
Type: PDF
 17-lm-lloLm-LLO Immunotherapies Targeting Multiple Antigens and Their Impact on Different Mechanisms in the Tumor Microenvironment
Uploaded: Nov 10, 2014
Type: PDF
 18-ascoASCO Annual Meeting 2014 Poster
Uploaded: May 31, 2014
Type: PDF
 19-americanAmerican Society of ClinicalOncology Annual Meeting 2013 Poster
Uploaded: Feb 27, 2014
Type: PDF
 20-societySociety for Immunotherapy of Cancer Annual Meeting 2013 Poster
Uploaded: Nov 8, 2013
Type: PDF
ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer.
21-society-b Society for Immunotherapy of Cancer Annual Meeting 2013 Poster
Uploaded: Nov 8, 2013
Type: PDF
Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy.